JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Scientific Breakthroughs and Industry Players in Anti-Aging Discovery

Syed Ansar Ahmed*[1], Mohammed Shakir Ghouse[2], Shital Sambhaji Sontakke[3], Rajratan Devrao Thorat[4], Pranali Pralhad Kalyankar[5]

[1] *Associate Professor, Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India*
[2] *Associate Professor, Department of Pharmacognosy and Phytochemistry, Aurangabad College of Pharmacy, Aurangabad, Maharashtra, India*
[3] *Assistant Professor, Department of Pharmacology, BK Patil Institute of Pharmacy, Taloja, Navi Mumbai, Maharashtra, India*
[4] *Research Scholar, Department of Pharmacology, Principal K M Kundnani College of Pharmacy, Mumbai, Maharashtra, India*
[5] *Assistant Professor, Department of Quality Assurance, School of Pharmacy, Swami Ramanand Teerth Marathwada University, Maharashtra, India*

Publication history: Received on 26th September 2025; Revised on 11th October 2025; Accepted on 14th October 2025

Article DOI: 10.69613/p95ppa64

Abstract: The pursuit of human longevity is a rigorously funded sector of biotechnology known as geroscience. This field operates on the premise that aging is a malleable biological process driven by distinct molecular hallmarks, rather than an inevitable decline. Current research focuses on intervening in these upstream mechanisms such as cellular senescence, mitochondrial dysfunction, and epigenetic alterations to extend healthspan, the period of life spent in good health. Significant capital influx from the technology sector has catalyzed this shift, leading to a unique convergence of computational biology, artificial intelligence, and regenerative medicine. The industry landscape is now populated by a mix of high-profile ventures backed by billionaires and agile biotech startups utilizing venture-building models to de-risk portfolio development. However, the market faces substantial friction from regulatory guidelines that do not currently recognize aging as a clinically treatable indication, forcing companies to target specific age-related pathologies as proxies for broader longevity claims. Despite these hurdles, the global anti-aging market is projected to expand robustly, driven by an aging global demographic and breakthroughs in proteomic and genomic interventions. This article reviews the scientific pillars supporting these therapies, the competitive strategies of the main industry stakeholders, and the economic forces shaping the commercialization of longevity science.

Keywords: Geroscience; Senolytics; Epigenetic Reprogramming; Healthspan; Longevity Biotechnology.

1. Introduction

The demographic structure of the global population is driven by declining fertility rates and substantial increases in life expectancy. By 2050, the number of individuals aged 65 and older is projected to surpass 1.5 billion, presenting a profound challenge to healthcare systems and economies worldwide [1]. This demographic shift represents a fundamental alteration in the global dependency ratio, placing immense strain on social safety nets and healthcare infrastructures that were originally designed for a younger population profile. As the ratio of retirees to working-age adults rises, the economic sustainability of current pension and healthcare models is increasingly called into question.

This "Silver Tsunami" is accompanied by a rising prevalence of multimorbidity, a complex clinical state where older adults simultaneously suffer from two or more chronic conditions such as cardiovascular disease, neurodegeneration, and metabolic disorders [2]. The burden of these accumulating pathologies is non-linear; the interaction between concurrent diseases often exacerbates frailty and accelerates functional decline, significantly complicating clinical management. Consequently, the modern geriatric patient is often subjected to polypharmacy and conflicting treatment protocols, where a therapy for one condition may inadvertently worsen another, leading to a cycle of diminishing quality of life.

Traditional pharmaceutical approaches have historically addressed these pathologies in isolation, treating specific symptoms or organ systems only after significant damage has occurred. This reactive paradigm functions as a "whack-a-mole" strategy that often extends lifespan without a commensurate improvement in healthspan the period of life spent in good health [3]. While modern medicine has been successful in preventing mortality from acute events like heart attacks, it has inadvertently expanded the period of late-life morbidity. This phenomenon results in an "expansion of disability," where the additional years gained are often spent managing chronic pain, cognitive decline, and dependency.

* Corresponding author: Syed Ansar Ahmed

In response to these limitations, the geroscience hypothesis posits that these chronic diseases share a common biological root: the aging process itself. Rather than viewing cancer, heart failure, and dementia as distinct entities with separate causes, this perspective identifies them as downstream manifestations of fundamental molecular deterioration. It may be possible to delay or prevent the onset of multiple age-related diseases simultaneously by intervening in the upstream molecular mechanisms of aging such as cellular senescence, mitochondrial dysfunction, and loss of proteostasis [4]. This approach aims to achieve a "compression of morbidity," effectively pushing the onset of disease and disability closer to the very end of life. This theoretical framework has catalyzed the emergence of a multi-billion-dollar industry focused on longevity and rejuvenation, moving the field from the fringes of speculative science to the forefront of biotechnology. The sector is characterized by a unique convergence of rigorous academic biology, pharmaceutical drug development, and Silicon Valley-style technological optimism [5]

2. Scientific Breakthroughs in Molecular Gerontology

The contemporary anti-aging industry is built upon the detailed characterization of the "Hallmarks of Aging," a framework first proposed in 2013 and subsequently updated to include emerging mechanisms like dysbiosis and chronic inflammation [6]. The translation of these hallmarks into therapeutic targets constitutes the primary R&D activity within the sector.



Figure 1. The Longevity Therapeutic Pipeline

2.1. Targeting Cellular Senescence and the SASP

Cellular senescence, a state of stable cell cycle arrest coupled with the secretion of pro-inflammatory factors, has emerged as a primary target for therapeutic intervention. Senescent cells accumulate in tissues with age, driven by telomere attrition, DNA damage, and oxidative stress [7]. While these cells play a beneficial role in wound healing and tumor suppression in younger organisms, their persistence in aged tissues contributes to a toxic microenvironment through the Senescence-Associated Secretory Phenotype (SASP) [8]. The SASP includes a myriad of cytokines (IL-6, IL-8), chemokines, and matrix metalloproteinases that degrade tissue architecture and induce senescence in neighboring healthy cells via paracrine signaling [9].

2.1.1. Senolytics

The First Generation Therapeutic strategies known as "senolytics" aim to selectively induce apoptosis in senescent cells. These compounds exploit the fact that senescent cells rely heavily on pro-survival pathways, such as the BCL-2 family, to resist cell death despite their damaged state [10]. Early senolytic agents, including the tyrosine kinase inhibitor dasatinib and the plant flavonoid quercetin, demonstrated the ability to reduce senescent cell burden in murine models, leading to improved cardiac function and physical endurance [11]. However, these first-generation agents largely lack cell-type specificity, raising concerns about off-target toxicity in human applications [12].

2.1.2. Second-Generation and Immuno-Senolytics

To address specificity, the field is advancing toward second-generation senolytics that utilize targeted delivery systems. One promising approach involves the use of galacto-oligosaccharide-coated nanoparticles that release cytotoxic drugs only upon degradation by senescence-associated beta-galactosidase (SA-β-gal), an enzyme highly overexpressed in senescent cells [13]. Furthermore, "immuno-senolytics" are being developed to harness the immune system to clear senescent cells. Chimeric Antigen Receptor (CAR) T-cell therapies, originally developed for cancer, are being engineered to recognize surface antigens specific to senescent cells, such as uPAR (urokinase-type plasminogen activator receptor), offering a potentially more precise clearance mechanism [14].

Table 1. The Molecular Hallmarks of Aging and Novel Therapeutic Targets

Hallmark of Aging	Biological Mechanism	Therapeutic Strategy	Investigational Agents
Cellular Senescence	Accumulation of non-dividing cells that secrete pro-inflammatory factors (SASP), damaging surrounding tissue.	Senolytics: Induce apoptosis in senescent cells. Senomorphics: Suppress the SASP without killing the cell.	Dasatinib + Quercetin (D+Q), Fisetin, Navitoclax, CAR-T cells targeting uPAR.
Epigenetic Alterations	Loss of histone modifications and DNA methylation patterns, leading to deregulated gene expression.	Epigenetic Reprogramming: Resetting methylation clocks to a youthful state.	Yamanaka Factors (OSK), DNA methyltransferase inhibitors.
Mitochondrial Dysfunction	Decline in mitochondrial efficiency, increased ROS production, and bioenergetic failure.	Mitophagy Inducers: Enhance removal of damaged mitochondria. NAD+ Boosters: Restore coenzyme levels.	Urolithin A, Nicotinamide Riboside (NR), Nicotinamide Mononucleotide (NMN).
Loss of Proteostasis	Accumulation of misfolded proteins and aggregates (e.g., amyloid plaques) due to failed autophagy.	Autophagy Activators: Stimulate cellular recycling processes.	Rapamycin (mTOR inhibitors), Spermidine, Metformin.
Nutrient Sensing Deregulation	Altered signaling in insulin/IGF-1, mTOR, AMPK, and sirtuin pathways, affecting metabolism.	Caloric Restriction Mimetics: Mimic the benefits of fasting.	Metformin, Rapalogs, Resveratrol, SGLT2 inhibitors.

Table 2. Selected Pivotal Clinical Trials Targeting Aging Mechanisms

Trial Name / ID	Intervention	Mechanism of Action	Target Indication (Proxy for Aging)	Phase	Significance
TAME (Targeting Aging with Metformin)	Metformin	AMPK activation; Insulin sensitization; Anti-inflammatory.	Age-related multimorbidity (composite endpoint).	Phase 4 (Planned)	First trial aiming to validate "aging" as a modifiable indication with the FDA.
BEHOLD (NCT04858135)	UBX1325	Bcl-xL inhibitor (Senolytic).	Diabetic Macular Edema (DME).	Phase 2	Tests efficacy of clearing senescent cells in the eye to restore vision.
Affinity (NCT04476953)	Fisetin	Natural Senolytic / Flavonoid.	Frailty and inflammation in older adults.	Phase 2	Evaluates safety and impact on frailty biomarkers in a geriatric population.
PEARL (NCT04475512)	Rapamycin	mTOR inhibition.	Ovarian aging and healthy longevity.	Phase 2	Investigates dosing regimens to extend fertility and delay menopause.
Restoration of Mitochondrial Function	Urolithin A	Mitophagy activator.	Muscle endurance and mitochondrial health.	Phase 1/2	Clinical validation of nutrient-derived compounds to improve muscle function in elderly.

2.2. Epigenetic Reprogramming and Methylation Clocks

Perhaps the most radical advancement in longevity science is the application of partial epigenetic reprogramming. This approach is grounded in the information theory of aging, which suggests that aging is driven by the loss of epigenetic information the "software" that tells a cell which genes to express rather than the accumulation of genetic mutations [15].

2.2.1. Partial Reprogramming via Yamanaka Factors

Research has shown that the expression of four transcription factors Oct4, Sox2, Klf4, and c-Myc (OSKM) can revert terminally differentiated adult cells into induced pluripotent stem cells (iPSCs) [16]. While continuous expression leads to dedifferentiation and tumorigenesis (teratoma formation), transient or cyclic expression of these factors (often excluding c-Myc to improve safety) has been shown to rejuvenate cells without erasing their identity [17]. This "partial reprogramming" restores youthful gene expression patterns and reverses age-related physiological decline in the optic nerve and other tissues in vivo [18].

2.2.2. Epigenetic Clocks as Biomarkers

The efficacy of reprogramming and other interventions is increasingly measured using epigenetic clocks. Developed by Steve Horvath and others, these clocks analyze DNA methylation levels at specific cytosine-guanine dinucleotide (CpG) sites to estimate biological age with high correlation to chronological age [19]. Second-generation clocks, such as GrimAge and PhenoAge, have been trained on mortality data and physiological biomarkers, making them more predictive of health outcomes and lifespan than chronological age alone [20]. These biomarkers are critical for clinical trials, as they provide a surrogate endpoint that allows researchers to assess the effectiveness of an anti-aging intervention in a timeframe significantly shorter than human lifespan [21].

2.3. Nutrient Sensing, Mitochondrial Function, and Autophagy

Metabolic dysregulation is a central feature of aging, manifesting as a progressive decline in the body's ability to maintain homeostasis in response to nutrient fluctuations. This dysfunction is driven by the impairment of highly conserved nutrient-sensing pathways specifically the Insulin/IGF-1 signaling (IIS) pathway, mTOR (mechanistic target of rapamycin), AMPK (AMP-activated protein kinase), and sirtuins which evolved to coordinate cell growth and repair with resource availability. As these pathways become deregulated over time, they contribute to mitochondrial dysfunction, characterized by a loss of respiratory chain efficiency, reduced ATP production, and an increase in the generation of reactive oxygen species (ROS). This bioenergetic failure not only deprives tissues of necessary energy but also initiates retrograde signaling that exacerbates cellular senescence and systemic inflammation [22].

2.3.1. NAD+ Metabolism and Sirtuin Activation

Nicotinamide adenine dinucleotide (NAD+) serves a dual role as a critical coenzyme for cellular metabolism (fueling glycolysis and oxidative phosphorylation) and as an obligate substrate for sirtuins, a family of NAD+-dependent deacetylases that regulate gene expression, DNA repair, and genomic stability [23]. However, NAD+ levels decline precipitously with age, a phenomenon driven by a "double hit" mechanism: a reduction in biosynthesis via the salvage pathway (mediated by the enzyme NAMPT) and a dramatic increase in consumption by NAD+-degrading enzymes such as CD38 and PARPs, which are upregulated in response to chronic inflammation and accumulating DNA damage [24]. This systemic deficit compromises sirtuin activity, accelerating epigenetic aging and metabolic rigidity. Consequently, a robust market has emerged for NAD+ boosters, particularly precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which aim to bypass the enzymatic bottlenecks in NAD+ synthesis. While preclinical models demonstrate potent rejuvenation effects, clinical investigations are currently assessing whether restoring NAD+ levels can translate into improved insulin sensitivity and vascular function in older adults, though issues regarding the bioavailability, stability, and cellular uptake of these precursors remain significant pharmacokinetic challenges to widespread therapeutic success [25].

2.3.2. Autophagy and Proteostasis

The maintenance of the proteome the entire set of proteins expressed by a genome is essential for cellular health. Aging is associated with a collapse in proteostasis, leading to the accumulation of misfolded proteins and aggregates implicated in neurodegenerative diseases [26]. Autophagy, the cellular "recycling" process, declines with age but can be upregulated pharmacologically. Rapamycin, an mTOR inhibitor, is the gold standard for autophagy induction and has consistently extended lifespan in model organisms ranging from yeast to mice [27]. Efforts are now focused on developing "rapalogs" analogs of rapamycin with reduced side effects (such as immunosuppression) to enable long-term preventative use in humans [28].

2.4. Artificial Intelligence in Longevity Drug Discovery

The complexity of aging biology, which involves the dynamic interaction of thousands of genes, metabolites, and proteins across different tissues and timescales, far exceeds the analytical capacity of traditional reductionist biology. Consequently, artificial intelligence (AI) and machine learning have become indispensable tools in the longevity discovery pipeline. Deep learning models, capable of processing high-dimensional "omics" data, are being trained on vast longitudinal datasets to identify non-obvious biomarkers of aging and predict the safety and efficacy profiles of potential geroprotectors [29]. Beyond analysis, companies are utilizing generative chemistry platforms and generative adversarial networks (GANs) to design molecules de novo. These AI-driven systems can optimize chemical structures to target specific aging pathways with higher affinity and selectivity than compounds found in existing chemical libraries, significantly compressing the timeline of drug development [30]. Furthermore, AI is proving instrumental in the move toward precision geroscience by stratifying patient populations for clinical trials. By analyzing an individual's unique biological noise, AI can determine their specific "aging type" (e.g., metabolic ager vs. immune ager), ensuring that interventions are tested in individuals most likely to respond, thereby maximizing the statistical power and success rate of clinical trials [31].

3. Global Industry Players

The commercialization of longevity science has given rise to a diverse industrial ecosystem, characterized by varying business models and risk appetites.

3.1. The Silicon Valley Model

A distinctive feature of the anti-aging sector is the prominence of "moonshot" research institutes funded by technology billionaires. These organizations operate outside the traditional constraints of academic grants or immediate shareholder returns. Altos Labs, backed by billions in initial funding, exemplifies this model, focusing intensively on cellular rejuvenation programming [32]. Similarly, Calico Life Sciences, a subsidiary of Alphabet, pursues a long-term strategy to map the biology of aging, leveraging advanced computing and partnerships with pharmaceutical entities like AbbVie to bridge the gap between basic discovery and clinical application [33]. These entities prioritize deep scientific understanding, betting that solving the fundamental biology of aging will yield a dominant intellectual property position in the future bio-economy.



Figure 2. The Anti-Aging Industry Ecosystem & Value Chain

3.2. The Biotech Ecosystem

Asset-Centric Development In contrast to the broad exploratory mandate of the tech-funded giants, independent biotechnology companies typically adopt a more focused, asset-centric approach. Companies like Unity Biotechnology have pioneered the clinical testing of senolytics, targeting specific localized indications such as osteoarthritis and diabetic macular edema to prove the safety and efficacy of the mechanism [34]. Although early trials have faced mixed results, they have provided invaluable data on the clinical translation of senolytic therapies. Other players, such as BioAge Labs, utilize a platform approach based on human longevity data to identify and validate targets that are then matched with proprietary drug candidates [35].

3.3. Venture-Building and Portfolio Models

To mitigate the high attrition rates inherent in drug discovery, a novel organizational structure known as the "venture-building" or "hub-and-spoke" model has gained prominence. Unlike traditional biotech firms that often rely on a single lead candidate, entities such as Cambrian Bio and Juvenescence aggregate multiple subsidiary companies under one umbrella [36]. Each subsidiary focuses on a distinct hallmark of aging ranging from mitochondrial uncoupling to extracellular matrix restoration thereby diversifying the risk profile. This structure allows the parent company to centralize resources for clinical operations and manufacturing while maintaining the agility of small, focused teams for scientific execution [37]. For instance, Cambrian Bio's pipeline includes assets targeting mTOR signaling for metabolic health alongside separate programs for tissue regeneration, effectively creating a diversified portfolio of longevity assets that can be divested or partnered individually as they reach clinical maturity.

Table 3. Comparison of Leading Anti-Aging Biotechnology Companies (2025)

Company	Headquarters	Technology	Business Model	Partnerships
Altos Labs	San Diego, CA	Cellular rejuvenation programming via induced pluripotent stem cell (iPSC) technology.	Deep Research Institute: High-capital, long-horizon basic science.	Funded by Jeff Bezos and Yuri Milner ($3B+ initial capital).
Calico Life Sciences	S. San Francisco, CA	Mapping the biology of aging; targeting neurodegeneration and cancer.	R&D Partnership: Operates as an Alphabet subsidiary with AbbVie collaboration.	Alphabet Inc. (Google), AbbVie.
Unity Biotechnology	S. San Francisco, CA	Senolytic medicines for ophthalmologic and neurologic diseases (e.g., UBX1325).	Asset-Centric: Clinical development of specific drug candidates.	Publicly traded (NASDAQ: UBX); backed by Amazon, Mayo Clinic.
Cambrian Bio	New York, NY	Distributed development of assets targeting the hallmarks of aging (Hub-and-Spoke).	Venture Builder: Holding company for multiple subsidiary biotechs.	Private Venture Capital; multi-asset portfolio approach.
Insilico Medicine	Hong Kong / NY	AI-driven drug discovery for fibrosis and age-related targets.	AI Platform: Generative adversarial networks (GANs) for target ID.	Warburg Pincus, WuXi AppTec, unrelated strategic investors.

3.4. Strategic Partnerships

While startups drive early-stage innovation, large pharmaceutical corporations have adopted a strategy of "external innovation" to engage with the longevity sector without fully committing to the regulatory uncertainty of anti-aging labels. Companies like Novartis, AbbVie, and Pfizer are increasingly establishing partnerships or equity stakes in longevity-focused biotechs to access emerging biology relevant to their core therapeutic areas [38]. For example, the collaboration between AbbVie and Calico Life Sciences aims to discover therapeutics for age-related neurodegeneration and cancer, effectively using age-related disease as a commercially viable entry point for geroprotective technologies. This symbiotic relationship allows established players to leverage the risk-taking capacity of startups while providing the necessary capital and regulatory infrastructure to scale successful interventions [39].

4. Market Dynamics and Economics

The global market for anti-aging therapeutics and associated technologies is experiencing robust expansion, driven by the convergence of demographic pressure and technological capability.

4.1. Global Market Valuation and Regional Trends

Market intelligence reports estimate the global anti-aging product market to be valued between $60 billion and $80 billion in 2025, with projections suggesting it could exceed $120 billion by 2030, registering a compound annual growth rate (CAGR) of approximately 7-8% [40]. North America currently dominates the market, accounting for over 35% of global revenue, attributed to high consumer awareness, significant healthcare expenditure, and a dense concentration of biotechnology firms [41]. However, the Asia-Pacific region is poised to witness the fastest growth rate over the coming decade. Rapidly aging populations in Japan, South Korea, and China, coupled with increasing disposable income and a cultural propensity for preventative health measures, are driving substantial demand for both aesthetic and systemic anti-aging interventions [42].

4.2. The Regulatory "Valley of Death" and the TAME Trial

A critical determinant of future market dynamics is the regulatory classification of aging. Currently, major regulatory bodies such as the U.S. Food and Drug Administration (FDA) do not recognize aging as a treatable indication, forcing developers to target specific surrogates or distinct pathologies. This regulatory "valley of death" creates a high barrier to entry for preventative therapies. The "Targeting Aging with Metformin" (TAME) trial represents a landmark effort to overcome this hurdle. Designed to test whether metformin can delay the onset of age-related multimorbidity in 3,000 older adults, TAME aims to establish a regulatory precedent for a composite endpoint of aging [43]. If successful, this trial could validate a pathway for "geroprotectors" to be approved as preventative medicines, fundamentally expanding the total addressable market from sick patients to the entire aging population.



Figure 3. The Geroscience Paradigm Shift.

Table 4. Global Anti-Aging Market Segmentation and Growth Projections (2025–2035)

Market Segment	2025 Estimated Value (USD Billion)	2035 Projected Value (USD Billion)	CAGR (%)	Growth Drivers
Anti-Senescence (Senolytics)	$0.5 B	$4.2 B	~23%	Clinical validation of senolytics for fibrotic and ophthalmic diseases.
Metabolic & Mitochondrial Health	$8.4 B	$18.1 B	~8%	Rising consumer adoption of NAD+ boosters (NMN/NR) and metabolic supplements.
Stem Cell & Regenerative Therapy	$14.2 B	$45.6 B	~12%	Advances in tissue engineering and organ regeneration technologies.
Aesthetic & Dermatologicals	$22.1 B	$38.5 B	~5.7%	Persistent demand for non-invasive cosmetic procedures and skin rejuvenation.
Total Global Market	Approximately $60 B	Approximately $120 B	~7.2%	Aging global demographics (Silver Tsunami) and rising disposable income in APAC.

Source: Data estimates are synthesized and aggregated from 2024–2025 market intelligence reports, specifically Grand View Research [40], Mordor Intelligence [41], and Fact.MR [42].

4.3. Socioeconomic Drivers

The economic imperative for anti-aging interventions extends beyond corporate profits to macroeconomic stability. The "Silver Economy" is reshaping fiscal policies as nations grapple with the costs of pension obligations and geriatric healthcare. The "longevity dividend" hypothesis suggests that extending healthspan by just one year could generate trillions of dollars in economic value by keeping older adults productive and reducing the burden of dependency [44]. Consequently, governments and insurers are beginning to view longevity science not as a luxury but as a necessary instrument for economic sustainability. Insurance providers are increasingly exploring "longevity-linked" products that incentivize policyholders to adopt health-extending behaviors or therapies, aligning financial risk management with biological health maintenance [45].

5. Conclusion

The global competitiveness of anti-aging discovery is accelerating, fueled by a convergence of biological breakthroughs and technological capital. While the scientific community has successfully delineated the mechanisms of aging, the translation of these insights into approved therapies remains a complex endeavor. The industry is bifurcated between deep-pocketed research institutes pursuing radical rejuvenation and agile startups navigating the current regulatory framework through specific disease indications. As clinical data matures and regulatory pathways evolve, the anti-aging sector is poised to transform from a speculative frontier into a cornerstone of modern medicine, fundamentally altering human health trajectories and economic structures.

References

[1] United Nations Department of Economic and Social Affairs. World Population Prospects 2024: Summary of Results. New York: United Nations; 2024.

[2] Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709-13.

[3] Olshansky SJ. From lifespans to healthspans. JAMA. 2018;320(13):1323-4.

[4] López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-217.

[5] Zhavoronkov A. Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. Mol Pharm. 2018;15(10):4311-3.

[6] López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-78.

[7] Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al. Cellular senescence: defining a path forward. Cell. 2019;179(4):813-27.

[8] Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685-705.

[9] Childs BG, Durik M, Baker DJ, van Deursen JM. Senescent cells: an emerging target for diseases of aging. Nat Rev Drug Discov. 2017;16(10):718-35.

[10] Zhu Y, Tchkonia T, Pirtskhalava T, Gower AC, Ding H, Giorgadze N, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-58.

[11] Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-56.

[12] Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-36.

[13] Muñoz-Espín A, Rovira M, Galiana I, Giménez C, Lozano-Torres B, Paez-Ribes M, et al. A versatile drug delivery system targeting senescent cells. EMBO Mol Med. 2018;10(9):e9355.

[14] Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127-32.

[15] Sinclair DA, LaPlante M. Lifespan: Why We Age and Why We Don't Have To. New York: Atria Books; 2019.

[16] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76.

[17] Ocampo A, Reddy P, Martinez-Redondo P, Platero-Luengo A, Hatanaka F, Hishida T, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell. 2016;167(7):1719-33.

[18] Lu Y, Brommer B, Tian X, Krishnan A, Meer M, Wang C, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-9.

[19] Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.

[20] Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303-27.

[21] Belsky DW, Caspi A, Ars CL, Baccarelli AA, Corcoran DL, Gao X, et al. Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm. eLife. 2020;9:e54870.

[22] Partridge L, Fuentealba M, Kennedy BK. The quest to slow ageing through drug discovery. Nat Rev Drug Discov. 2020;19(8):513-32.

[23] Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-71.

[24] Camacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127-39.

[25] Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.

[26] Hipp MS, Park SH, Hartl FU. Proteostasis impairment in protein-misfolding diseases and aging. Trends Cell Biol. 2014;24(9):506-14.

[27] Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-5.

[28] Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.

[29] Zhavoronkov A, Mamoshina P, Vanhaelen Q, Scheibye-Knudsen M, Moskalev A, Aliper A. Deep biomarkers of aging and longevity: from research to applications. Aging (Albany NY). 2019;11(22):10771-80.

[30] Wong F, de la Fuente-Nunez C, Collins JJ. Discovering small-molecule senolytics with deep learning. Nat Aging. 2023;3:734–50.

[31] Ahadi S, Zhou W, Schüssler-Fiorenza Rose SM, Sailani MR, Contrepois K, Avina M, et al. Personal aging markers and ageotypes revealed by deep longitudinal profiling. Nat Med. 2020;26(1):83-90.

[32] Regalado A. Altos Labs and the quest for immortality. MIT Technology Review [Internet]. 2022. Available from: https://www.technologyreview.com/2022/09/07/1059039/altos-labs-quest-for-immortality/

[33] Calico Life Sciences. Calico and AbbVie announce extension of collaboration [Press Release]. South San Francisco: Calico Life Sciences; 2021 Jul.

[34] Unity Biotechnology. UNITY Biotechnology Announces Positive Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema [Press Release]. South San Francisco: Unity Biotechnology; 2022.

[35] BioAge Labs. BioAge Announces First Patient Dosed in Phase 2 Study of BGE-105 for Muscle Atrophy [Press Release]. Richmond, CA: BioAge Labs; 2022.

[36] Boekstein N, Barzilai N, Bertram A, Betts-LaCroix J, Fortney K, Helliwell SB, et al. Defining a longevity biotechnology company. Nat Biotechnol. 2023;41:1053-5.

[37] Mellon J, Chalabi A. Juvenescence: Investing in the Age of Longevity. Petersfield: Harriman House; 2017.

[38] PwC. Pharma 2020: The vision - Which path will you take? New York: PricewaterhouseCoopers; 2019.

[39] AbbVie Inc. 2023 Annual Report on Form 10-K. North Chicago: AbbVie Inc.; 2024.

[40] Grand View Research. Anti-Aging Market Size, Share & Trends Analysis Report By Product, By Region, And Segment Forecasts, 2024-2030. San Francisco: Grand View Research; 2024.

[41] Mordor Intelligence. Anti-Aging Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024 - 2029). Hyderabad: Mordor Intelligence; 2024.

[42] Fact.MR. Anti-Aging Products Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2024 to 2034. Rockville: Fact.MR; 2024.

[43] Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-5.

[44] Scott AJ, Ellison M, Sinclair DA. The economic value of targeting aging. Nat Aging. 2021;1:616-23.

[45] World Economic Forum. Future-Proofing the Longevity Economy: Innovations and Key Trends. Geneva: World Economic Forum; 2024.